Senegal Sequences First 40 Human Genomes, Launches Cancer Test

Scientists in Senegal just unlocked a powerful new weapon in the fight against cancer, and it could transform healthcare across West Africa.

The Institut Pasteur de Dakar successfully sequenced the first 40 complete human genomes in Senegal, marking a historic leap forward for precision medicine in the country. The new platform will enable doctors to test patients for genetic predisposition to early-onset breast cancer and other heritable conditions that have been difficult to diagnose in the region.

This milestone took decades of groundwork to reach. The first human genome was sequenced in 2001, but the first complete genome sequenced on African soil didn't happen until 2013 in South Africa.

Now Senegal joins an elite group of African nations using cutting-edge dual sequencing technologies for whole genome analysis. The institute deployed state-of-the-art Illumina and Oxford Nanopore platforms, leveraging years of expertise in pathogen genomics and laboratory systems.

The real-world impact extends far beyond the laboratory walls. Institut Pasteur de Dakar is combining this scientific breakthrough with community action, distributing cervical cancer screening vouchers and supporting national HPV vaccination campaigns across multiple regions.

Dr. Moussa Moise Diagne, a research scientist at the institute, explained how years of tracking disease outbreaks laid the foundation for this achievement. "By leveraging our expertise in pathogen genomics, we are now building the foundations of clinical genomics capacity that will transform how we detect and understand diseases in Senegal," he said.

The platform initially focuses on breast cancer detection but will expand to other cancer types in the future. This matters enormously for a continent where late diagnosis remains a major barrier to cancer survival.

The Ripple Effect

This breakthrough reaches far beyond Senegal's borders. By developing genomic medicine capacity in West Africa, the Institut Pasteur de Dakar is helping ensure that African patients benefit from the same precision health tools available in wealthier nations.

The initiative reflects what CEO Dr. Ibrahima Socé Fall calls "health sovereignty," where African institutions lead continental health innovations rather than depending entirely on external solutions. The work aligns with broader genomics initiatives from the Africa CDC, building a network of expertise across the continent.

Dr. Alexander Ross from the University of Southampton noted the platform's life-saving potential: "Developing these technologies will optimize patient treatments, prevent cancers, and save lives." The pilot study provides a blueprint that other African nations can follow.

For Senegalese women especially, this means access to genetic testing that could catch cancer years earlier, when treatment is most effective. Combined with community screening programs and prevention campaigns, the integrated approach tackles cancer from multiple angles simultaneously.

This is what health equity in action looks like: world-class science meeting urgent community needs, all developed and delivered by African scientists for African populations.